4DMT Reports Full Year 2024 Financial Results, Operational Highlightsand Expected Upcoming Milestones
February 28, 2025 16:05 ET | Source: 4D Molecular Therapeutics, Inc. Presented…
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
February 08, 2025 14:30 ET | Source: 4D Molecular Therapeutics, Inc. 3E10…
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
January 29, 2025 08:00 ET | Source: 4D Molecular Therapeutics, Inc. Initial…